An observed surrogate endpoint is often used to predict treatment effect on an unobserved true endpoint when the true endpoint is difficult or expensive to be measured. Although there have been several criteria for surrogate endpoints, they cannot avoid the surrogate paradox, which means that a treatment has a positive effect on a surrogate and the surrogate has a positive effect on an endpoint, but the treatment has a negative effect on the endpoint. To avoid the surrogate paradox, some investigators provided criteria for a single surrogate which blocks the path from the treatment to the endpoint. This requires that there is only a single path from treatment to endpoint and the surrogate can block the single path. However, in many applications, a treatment may affect an endpoint through several paths. In this paper, we propose some criteria for multiple surrogates. We make use of stochastic orders of random vectors to give criteria for multiple surrogates to avoid the surrogate paradox and to predict the sign of treatment effect on the unobserved true endpoint. Further under the conditional independence of the treatment and the true endpoint given the multiple surrogates, we propose some sufficient conditions for the sign equivalence of treatment effects on the surrogates and on the true endpoint. Furthermore, Statistica Sinica: Newly accepted Paper (accepted version subject to English editing)
[1]
Z. Geng,et al.
Sufficient conditions for concluding surrogacy based on observed data
,
2011,
Statistics in medicine.
[2]
M. Drton.
Discrete chain graph models
,
2009,
0909.0843.
[3]
Tyler J Vanderweele,et al.
Surrogate Measures and Consistent Surrogates
,
2013,
Biometrics.
[4]
Zhi Geng,et al.
Criteria for surrogate end points based on causal distributions
,
2010
.
[5]
D. Rubin.
Estimating causal effects of treatments in randomized and nonrandomized studies.
,
1974
.
[6]
Michael G Hudgens,et al.
Evaluating Candidate Principal Surrogate Endpoints
,
2008,
Biometrics.
[7]
D. Rubin,et al.
Identification of Causal Effects Using Instrumental Variables: Rejoinder
,
1996
.
[8]
R. Prentice.
Surrogate endpoints in clinical trials: definition and operational criteria.
,
1989,
Statistics in medicine.
[9]
James N. Druckman,et al.
Framing and Deliberation: How Citizens' Conversations Limit Elite Influence
,
2003
.
[10]
J. Shanthikumar,et al.
Multivariate Stochastic Orders
,
2007
.
[11]
Zhi Geng,et al.
Criteria for surrogate end points
,
2007
.